Volume : 13, Issue : 05, May – 2026
Title:
EXPERIMENTAL ANIMAL MODELS IN ONCOLOGY: A REVIEW OF TUMOR PROGRESSION AND THERAPY
Authors :
Dr. Tazneem B, Ehsaan Ahmed Ghori*, Yasmine Abdul Aziz,Mohd Abdul Omer, Mohd Arif Ahmed khan
Abstract :
Cancer remains one of the leading causes of mortality worldwide and continues to represent a major challenge for healthcare systems due to its complex and multifactorial nature. Despite significant advancements in diagnosis and treatment, the global burden of cancer continues to rise, emphasizing the need for a deeper understanding of its underlying mechanisms and the development of more effective therapeutic strategies. Experimental models have become essential tools in cancer research, with animal models playing a particularly important role in bridging the gap between in vitro studies and clinical applications.
Animal models provide a dynamic and physiologically relevant system that allows researchers to study tumor initiation, progression, invasion, and metastasis within a living organism. These models also enable the evaluation of tumor responses to various therapeutic interventions, thereby contributing to the development of safer and more effective anticancer drugs. In addition, animal models facilitate the investigation of molecular and genetic mechanisms underlying carcinogenesis, as well as interactions between tumor cells and the host microenvironment, including immune responses and angiogenesis.
Various types of animal models are widely used in oncology research, including spontaneous tumor models, chemically induced tumor models, xenograft models, orthotopic models, patient-derived xenografts, and genetically engineered mouse models. Each of these models offers unique advantages and helps researchers explore different aspects of tumor biology, ranging from genetic alterations to treatment responses. These models have significantly advanced modern cancer therapies, including targeted therapy, immunotherapy, and gene-based treatments.
Despite certain limitations, including differences between animal and human biology, animal models remain indispensable in cancer research. They continue to provide valuable insights that support the discovery, evaluation, and optimization of novel diagnostic and therapeutic strategies. Overall, animal models play a critical role in improving our understanding of cancer and advancing the development of more effective and personalized treatment approaches.
Keywords:Animal models; Cancer research; Spontaneous tumor models; Chemically induced tumor models; Xenograft models; Orthotopic tumor models; Patient-derived xenograft (PDX); Genetically engineered mouse models (GEMM); Humanized mouse models.
Cite This Article:
Please cite this article in press Ehsaan Ahmed Ghori et al., Experimental Animal Models In Oncology: A Review Of Tumor Progression And Therapy.., Indo Am. J. P. Sci, 2026; 13(05).
REFERENCES:
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians.
2013;63(1):11–30. doi:10.3322/caac.21166.
2. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer.
2013;108:479-485.
3. Aizawa K, Liu C, Tang S, Veeramachaneni S, Hu KQ, Smith DE, et al. Tobacco carcinogen induces both lung cancer and nonalcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation. Int J Cancer. 2016;139(5):1171-1181.
4. Cumberbatch MGK, Cox A, Teare D, et al. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1(9):1282-1290.
5. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer.
2006;118(12):30303044. doi:10.1002/ijc.21731.
6. Seto M, Homma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer Sci.
2010;101(3):573-578.
7. Guo H, Xu X, Zhang J, Du Y, Yang X, He Z, et al. The pivotal role of preclinical animal models in anticancer drug discovery and personalized cancer therapy strategies. Pharmaceuticals (Basel).
2024;17(8):1048. Doi:10.3390/ph17081048.
8. Mendes N, Dias Carvalho P, Martins F, Mendonça S, Malheiro AR, Ribeiro A, et al. Animal models to study cancer and its microenvironment. Adv Exp Med Biol. 2020;1219:389-401. doi:10.1007/978-3-03034025-4_20.
9. Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16:759-773.
10. Ingle AD. Animal models for cancer research and treatment. J Lab Anim Sci. 2021;4(2):18-23.
11. Onaciu A, Munteanu R, Munteanu VC, Gulei D, Raduly L, Feder RI, et al. Spontaneous and induced animal models for cancer research. Diagnostics (Basel). 2020;10(9):660. doi:10.3390/diagnostics10090660.
12. Rangarajan A, Weinberg RA. Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer. 2003;3(12):952-959. Doi:10.1038/nrc1235.
13. Sharpless NE, DePinho RA. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006;5(9):741-754. Doi:10.1038/nrd2110.
14. Richmond A, Su Y. Mouse xenograft models vs genetically engineered mouse models for cancer therapeutics. Dis Model Mech. 2008;1(2-3):78-82. Doi:10.1242/dmm.000976.
15. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity. Cancer Biol Ther. 2003;2(4):S134-S139.
16. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc.
2007;2(2):247250. Doi:10.1038/nprot.2007.25.
17. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages.
Eur J Cancer. 2004;40(6):852-857. doi:10.1016/j.ejca.2003.11.021.
18. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338-350.
Doi:10.1038/nrclinonc.2012.61.
19. Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998-1013. doi:10.1158/2159-8290.CD-14-0001.
20. Siolas D, Hannon GJ. Patient-derived tumor xenografts: Transforming clinical samples into mouse models.
Cancer Res. 2013;73(17):5315-5319. doi:10.1158/0008-5472.CAN-131069.
21. Walsh NC, Kenney LL, Jangalwe S, Aryee KE, Greiner DL, Brehm MA, et al. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017;12:187-215. doi:10.1146/annurev-pathol-052016-100332.
22. Zhitao L, Zheng W, Wang H, Cheng Y, Fang Y, Wu F, et al. Application of animal models in cancer research: Recent progress and future prospects. Cancer Manag Res. 2021;13:2455-2475.
Doi:10.2147/CMAR.S302565.
23. Mak IWY, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment.
Am J Transl Res. 2014;6(2):114–118.
24. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, et al. Interrogating open issues in cancer precision medicinewith patient-derived xenografts. Nat Rev Cancer. 2017;17(4):254-268.
Doi:10.1038/nrc.2016.140.
25. Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development. Nat Med. 2015;21(5):431-439. Doi:10.1038/nm.3853.
26. Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development. Nat Med. 2015;21(5):431-439. doi:10.1038/nm.3853.